UFC GYM(R) Sets the Stage for Unprecedented Global Expansion, Opening 45 Locations Worldwide in 2025
UFC GYM® is gearing up for an extraordinary 2025, opening more than 45 locations worldwide and increasing its global footprint to 42 total countries
LAS VEGAS, NV / ACCESS Newswire / February 27, 2025 / UFC GYM®, the groundbreaking extension of UFC®, will set a bold new standard for fitness in 2025, expanding its reach to new corners of the globe. As the fast-growing and dynamic brand continues to redefine the fitness and mixed martial arts industries, UFC GYM will open more than 45 locations worldwide this year, making its debut in Pakistan and Indonesia, and increasing its global footprint to 42 countries by year's end. The expansion will introduce UFC GYM to some of the world's most vibrant and rapidly evolving fitness markets, making its transformative fitness experience accessible to millions around the world.
Photos available to download , courtesy of UFC GYM®
From the heart of the U.S. to dynamic cities in North America, South America, Asia, Europe, the Middle East and beyond, UFC GYM is on a mission to deliver cutting-edge facilities, top-tier equipment and expert-led classes worldwide. As the brand continues its meteoric rise, UFC GYM is on track to open its 200th gym in 2025, spearheading a global fitness movement centered around innovation, community and mental empowerment. Among the highly anticipated new locations are: Be'er Sheva, Bat Yam and Gedera, Israel; Del Valle, Mexico; Centria Mall, Saudi Arabia; Manama, Bahrain; Berlin, Germany; Ajman, United Arab Emirates; Casablanca, Morocco; Guwahati, India; Almaty, Kazakhstan; and Voronezh, Russia.
'We're witnessing a powerful shift, as more and more people are drawn to our 'Train Different' philosophy,' said Adam Sedlack, CEO of UFC GYM. 'Our facilities are not just places to work out - they're transformative spaces where individuals challenge their limits, build their confidence and reinvent their approach to health and fitness. Every day we hear inspiring stories from our incredible members whose lives have been impacted by UFC GYM, both physically and mentally. Our mission is clear: to inspire people to become the best versions of themselves, pushing past barriers and realizing their full potential.'
This year, UFC GYM will unveil its cutting-edge Brazilian Jiu-jitsu studios, featuring nearly 2,500 square feet of space dedicated to practicing the dynamic discipline. This bold new franchise concept will combine one of mixed martial arts' most popular practices, BJJ, with UFC GYM's elite programming, making it more accessible to a larger fitness community. BJJ delivers a full-body workout while also building character and mental resilience, helping practitioners carry lessons from the mat into everyday life. With the launch of these state-of-the-art studios, passionate coaches and franchisees will have the opportunity to offer more resources to members, while capitalizing on the explosive growth of this rapidly rising fitness trend to maintain a competitive edge. UFC GYM models, now ranging from 2,000 square feet to more than 50,000 square feet with the addition of the BJJ studios, are thoughtfully designed to give members the tools they need to embrace their fighting spirit and achieve their fitness goals.
UFC GYM recently agreed to an exclusive partnership with Alta Global Group, a pioneering technology company dedicated to transforming the landscape of martial arts and combat sports training, to integrate Alta's innovative products across UFC GYM's extensive network of global gyms. The Alta Warrior Training Program provides an unparalleled opportunity for members to train like UFC athletes, combining the world's best in MMA and fitness in a fresh and innovative way to train and get fit. The curated 20-week regimen culminates in an exhilarating, fully sanctioned amateur MMA bout, an unparalleled 'bucket list' experience.
UFC GYM continues to redefine what it means to be more than just a gym - it's an experience that empowers and inspires. This rapid international growth reflects the increasing demand for UFC GYM and a shift in the fitness industry, where members seek more than just traditional gym amenities.
'We see everyone, from those that want to engage in our empowering classes like yoga, boxing, BJJ and full body recovery centers, all the way to some of the world's best Zumba, cycle and boot camp formats in the industry,' said Sedlack. 'Our gyms are equipped with state-of-the-art amenities and host some of the world's best coaches and fitness competitions.'
For those inspired by UFC GYM's growth and vision, opportunities to become a part of the brand through ownership are also available. With locations already being developed across continents, joining the UFC GYM franchise provides entrepreneurs with the chance to be part of a global leader in the fitness industry. For franchising information, visit www.ufcgymfranchise.com or contact [email protected] www.ufcgym.com.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
an hour ago
- Business Wire
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit
Yahoo
2 hours ago
- Yahoo
EthicAI Advisory Limited: Cambridge spinout launches new tool to boost confidence in AI
LONDON, June 9, 2025 /PRNewswire/ -- EthicAI Advisory Limited ("EthicAI"), a University of Cambridge spinout and global leader in the ethical and responsible assurance of artificial intelligence, has launched a cloud-based AI assurance SaaS platform to address ethical and trust issues around the adoption of AI, unlocking the technology's economic potential. AI models can create problems across a number of areas: Fairness and bias — AI systems can discriminate against certain groups including through hidden bias in training data Transparency — automating workflows can create 'black box' issues where algorithmic decision-making is opaque and consequently hard to understand and challenge Employee impacts — automation may unintentionally disempower, not augment, human workers if not designed carefully. The adoption of AI without enablement and literacy programmes can also erode company culture and employee motivation BeehAIve® scrutinises models and datasets against 15 ethical dimensions, assessing evidence across thousands of measurement points. The platform allows organisations to design, deploy and monitor autonomous systems that are optimised for success. BeehAIve® allows for technical stress-testing of model performance to improve reliability, robustness and security, while also recommending ways to reduce energy usage from AI. The platform enables assessment of models and systems against regional and national legislation including the EU AI Act, GDPR, the Korean AI Act, as well as industry-specific regulations and globally recognised AI standards. BeehAIve® then recommends how gaps can be filled, preparing for cross-border compliance while building stakeholder trust. The platform offers organisations a secure hub for their AI data, ensuring information remains safe and encrypted at all times. Tanya Goodin, Founder & CEO of EthicAI says: "BeehAIve® is a unique platform that enables organisations and their stakeholders to adopt AI with increased trust and confidence. Research shows that consumer confidence in AI has fallen by 8% globally over the past five years due to concerns about how AI is designed and built. BeehAIve® looks under the hood of organisations' AI models and systems — both in development and post deployment — to identify blind spots and weaknesses and provides actionable insights on how to mitigate and manage risks." For further information, contact: tanya@ or tim@ EthicAI Advisory Ltd EthicAI was formed in 2022 to build trust in AI by assuring models and systems to the highest ethical and responsible standards. EthicAI spun out of the University of Cambridge's Leverhulme Centre for the Future of Intelligence, with all the founding team previously engaged in cutting-edge AI ethics research at the university. The founders' leadership experience spans organisations including the BBC, Fidelity Investments, Barclays, Merrill Lynch, Deutsche Bank and UBS. Read more about the team here. EthicAI's cloud-based platform BeehAIve® will allow the company to scale its offer, and bring solutions to more organisations, more rapidly. It sits at the heart of the company's mission to ensure the ethical and responsible adoption of state-of-the-art AI systems — powering their success and helping to strengthen the UK's position as a leader in artificial intelligence. View original content: Sign in to access your portfolio


Business Upturn
2 days ago
- Business Upturn
Lupin gets U.S. FDA tentative approval for Generic Oxcarbazepine ER Tablets
Lupin Limited has announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Oxcarbazepine Extended-Release (ER) Tablets in 150 mg, 300 mg, and 600 mg strengths. These tablets are the generic equivalent of Oxtellar XR® ER Tablets by Supernus Pharmaceuticals and are indicated for the treatment of partial-onset seizures in patients aged 6 years and above. Lupin's version of the drug will be manufactured at its Nagpur facility in India. According to IQVIA MAT April 2025 data, Oxcarbazepine ER Tablets (RLD Oxtellar XR®) recorded estimated annual sales of USD 206 million in the United States, underscoring the potential market opportunity for Lupin. Headquartered in Mumbai, Lupin is a leading global pharmaceutical company with a strong footprint in the U.S. and India. The company focuses on a broad range of therapy areas including central nervous system disorders, respiratory, cardiovascular, anti-infective, and women's health. It operates 15 manufacturing sites and 7 research centers globally, supported by over 23,000 employees. Lupin continues to expand its U.S. portfolio of complex generics and remains committed to delivering high-quality, affordable medicines that improve health outcomes for patients around the world. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at